With a focus on alleviating human suffering and rescuing society from the ongoing opioid crisis, CerSci Therapeutics is poised to deliver a new generation of non-opioid medicines to treat acute postoperative and chronic neuropathic pain (painful diabetic neuropathy). CerSci Therapeutics announced in February that their Investigational New Drug (IND) application for CT-044 has received notification from the United States Food and Drug Administration (FDA) indicating that its Phase I safety and tolerability clinical trial may proceed. CT-044, a non-metal based, orally bioavailable, small molecule Radical Species Decomposition Accelerant (RSDAx) of peroxynitrite and hydrogen peroxide, is proposed for the treatment of acute and chronic pain, including acute post-surgical pain and painful diabetic neuropathy. CerSci's phase I study will commence clinical conduct in June with subject dosing commencing in July 2019.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
CT-044 (non-opioid analgesic)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):